Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of DeathEdward Abraham, William L. Macias, Barbara G. Utterback et al.|New England Journal of Medicine|2005Cited by 890
Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxisJoan Perelló, Carolina Salcedo, Patrick C. D’Haese et al.|British Journal of Pharmacology|2020Cited by 48
Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsisJean‐Louis Vincent, David P. Sundin, James M. O’Brien et al.|Critical Care|2006Cited by 41